Significantly lower expression of IL-33 was found in the lung tissue of COVID-19 patients compared with the control group [21], which may be related to the possibility of depletion of IL-33 as well as its degradation, which cannot be detected by commercially available antibodies. The gene discussed is IL33; the disease is COVID-19.